دورية أكاديمية
أعرض في EDS

Towards in vitro models for reducing or replacing the use of animals in drug testing.

التفاصيل البيبلوغرافية
العنوان: Towards in vitro models for reducing or replacing the use of animals in drug testing.
المؤلفون: Stresser DM; Quantitative, Translational & ADME Sciences, AbbVie, North Chicago, IL, USA. david.stresser@abbvie.com.; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ), . david.stresser@abbvie.com.; IQ Microphysiological Systems Affiliate (IQ-), . david.stresser@abbvie.com., Kopec AK; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Drug Safety Research & Development, Pfizer, Inc., Groton, CT, USA., Hewitt P; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Chemical and Preclinical Safety, Merck KGaA, Darmstadt, Germany., Hardwick RN; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Discovery Toxicology, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, San Diego, CA, USA., Van Vleet TR; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Investigative Toxicology and Pathology, AbbVie, North Chicago, IL, USA., Mahalingaiah PKS; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Investigative Toxicology and Pathology, AbbVie, North Chicago, IL, USA., O'Connell D; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; Global Animal Welfare, AbbVie, North Chicago, IL, USA.; IQ 3Rs (Replacement, Reduction, Refinement) Translational and Predictive Sciences Leadership Group., Jenkins GJ; Quantitative, Translational & ADME Sciences, AbbVie, North Chicago, IL, USA.; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Translational and ADME Sciences Leadership Group (TALG)., David R; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Clinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, UK., Graham J; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; Product Quality & Occupational Toxicology, Genentech, Inc., South San Francisco, CA, USA.; IQ DruSafe.; Safety Assessment, Genentech, Inc., South San Francisco, CA, USA., Lee D; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ 3Rs (Replacement, Reduction, Refinement) Translational and Predictive Sciences Leadership Group.; Safety Assessment, Genentech, Inc., South San Francisco, CA, USA., Ekert J; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; UCB Pharma, Cambridge, MA, USA., Fullerton A; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Investigative Toxicology, Genentech, Inc., South San Francisco, CA, USA., Villenave R; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Bajaj P; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Global Investigative Toxicology, Preclinical Safety, Sanofi, Cambridge, MA, USA., Gosset JR; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Pfizer, Inc, Cambridge, MA, USA., Ralston SL; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ 3Rs (Replacement, Reduction, Refinement) Translational and Predictive Sciences Leadership Group.; Preclinical Safety, AbbVie, North Chicago, IL, USA., Guha M; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Discovery Biology, Incyte, Wilmington, DE, USA., Amador-Arjona A; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Discovery Biology, Incyte, Wilmington, DE, USA., Khan K; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Clinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, UK., Agarwal S; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Investigative Toxicology, Early Development, Alnylam Pharmaceuticals, Cambridge, MA, USA., Hasselgren C; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ DruSafe.; Predictive Toxicology, Genentech, Inc., South San Francisco, CA, USA., Wang X; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Translational Safety & Bioanalytical Sciences, Amgen Research, Amgen Inc., South San Francisco, CA, USA., Adams K; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ 3Rs (Replacement, Reduction, Refinement) Translational and Predictive Sciences Leadership Group.; Laboratory Animal Resources, Incyte, Wilmington, DE, USA., Kaushik G; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Nonclinical Drug Safety, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA., Raczynski A; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Preclinical Safety Assessment, Vertex Pharmaceuticals, Inc, Boston, MA, USA., Homan KA; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ), . homan.kimberly@gene.com.; IQ Microphysiological Systems Affiliate (IQ-), . homan.kimberly@gene.com.; Complex in vitro Systems Group, Genentech, Inc., South San Francisco, CA, USA. homan.kimberly@gene.com.
المصدر: Nature biomedical engineering [Nat Biomed Eng] 2023 Dec 27. Date of Electronic Publication: 2023 Dec 27.
Publication Model: Ahead of Print
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Nature Country of Publication: England NLM ID: 101696896 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2157-846X (Electronic) Linking ISSN: 2157846X NLM ISO Abbreviation: Nat Biomed Eng Subsets: MEDLINE
أسماء مطبوعة: Publication: London : Springer Nature
Original Publication: [London] : Macmillan Publishers Limited, [2016]-
References: Avila, A. M. et al. Regul. Toxicol. Pharmacol. 139, 105345 (2023). (PMID: 3674632310.1016/j.yrtph.2023.105345)
ICH Guideline M3(R2) on Non-clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorisation for Pharmaceuticals: Step 5 (European Medicines Agency, 2013).
Strategic Plan to Promote the Development and Implementation of Alternative Test Methods Within the TSCA Program (US Environmental Protection Agency, 2018).
A Strategic Roadmap for Establishing New Approaches to Evaluate the Safety of Chemicals and Medical Products in the United States (ICCVAM, 2018).
Avila, A. M. et al. Regul. Toxicol. Pharmacol. 114, 104662 (2020). (PMID: 3232511210.1016/j.yrtph.2020.104662)
OECD Test Guidelines for Chemicals (OECD, accessed 24 October 2023); https://go.nature.com/3T4GMeV.
ICH Guideline M7(R2) on Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk: Step 5 (European Medicines Agency, 2023).
Butler, L. D. et al. Regul. Toxicol. Pharmacol. 87 (Suppl. 3), S1–S15 (2017).
Valentin, J. P. & Leishman, D. Regul. Toxicol. Pharmacol. 139, 105368 (2023). (PMID: 3684135010.1016/j.yrtph.2023.105368)
Schmeisser, S. et al. Environ. Int. 178, 108082 (2023). (PMID: 3742297510.1016/j.envint.2023.108082)
Parish, S. T. et al. Regul. Toxicol. Pharmacol. 112, 104592 (2020). (PMID: 3201796210.1016/j.yrtph.2020.104592)
Fabre, K. et al. Lab Chip 20, 1049–1057 (2020). (PMID: 3207302010.1039/C9LC01168D)
Vogt, N. Nat. Methods 18, 27 (2021). (PMID: 3340838710.1038/s41592-020-01026-x)
Ingber, D. E. Nat. Rev. Genet. 23, 467–491 (2022). (PMID: 35338360895166510.1038/s41576-022-00466-9)
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P. & Tagle, D. A. Nat. Rev. Drug Discov. 20, 345–361 (2021). (PMID: 3291333410.1038/s41573-020-0079-3)
Rumsey, J. W. et al. Adv. Ther. 5, 2200030 (2022). (PMID: 10.1002/adtp.202200030)
Clapp, N., Amour, A., Rowan, W. C. & Candarlioglu, P. L. Biochem. Soc. Trans. 49, 1881–1890 (2021). (PMID: 34397080842104910.1042/BST20210840)
Baran, S. W. et al. ALTEX 39, 297–314 (2022). (PMID: 35064273)
Kopec, A. K. et al. J. Toxicol. Sci. 46, 99–114 (2021). (PMID: 3364252110.2131/jts.46.99)
Cairns, J. et al. Front. Pharmacol. https://doi.org/10.3389/fphar.2023.1142581 (2023). (PMID: 10.3389/fphar.2023.11425813734629710279775)
Marx, U. et al. ALTEX 37, 365–394 (2020). (PMID: 321131847863570)
Vulto, P. & Joore, J. Nat. Rev. Drug Discov. 20, 961–962 (2021). (PMID: 3464603510.1038/s41573-021-00323-0)
Ewart, L. et al. Commun. Med. 2, 154 (2022). (PMID: 36473994972706410.1038/s43856-022-00209-1)
Proctor, W. R. et al. Arch. Toxicol. 91, 2849–2863 (2017). (PMID: 28612260551597110.1007/s00204-017-2002-1)
Schaller, T. H. et al. J. Immunother. Cancer 8, e000213 (2020). (PMID: 32273346725410910.1136/jitc-2019-000213)
Ji, Y. et al. Clin. Transl. Sci. 15, 2218–2229 (2022). (PMID: 35731955946857010.1111/cts.13355)
Dudal, S. et al. J. Immunother. 39, 279–289 (2016). (PMID: 2740494110.1097/CJI.0000000000000132)
Muller, P. Y., Milton, M., Lloyd, P., Sims, J. & Brennan, F. R. Curr. Opin. Biotechnol. 20, 722–729 (2009). (PMID: 1989682510.1016/j.copbio.2009.10.013)
Van Vleet, T. R., Liguori, M. J., Lynch, J. J. III, Rao, M. & Warder, S. SLAS Discov. 24, 1–24 (2019). (PMID: 3019674510.1177/2472555218799713)
Obach, R. S. Curr. Top. Med. Chem. 11, 334–339 (2011). (PMID: 2132006210.2174/156802611794480873)
Wang, J. & Urban, L. Drug Discov. World 73–86 (2004).
OTP INTERACT Meeting (FDA, 14 June 2023); https://go.nature.com/47S08bq.
PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2023 Through 2027 (FDA, 2022); https://go.nature.com/413kiwP.
Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program (FDA, 6 April 2023); https://go.nature.com/418CsNq.
Horner, S. et al. Regul. Toxicol. Pharmacol. 65, 334–343 (2013). (PMID: 2342291110.1016/j.yrtph.2013.02.002)
Phillips, J. A. et al. Lab Chip 20, 468–476 (2020). (PMID: 3198914510.1039/C9LC00925F)
Novak, R. et al. Nat. Biomed. Eng. 4, 407–420 (2020). (PMID: 31988458805786510.1038/s41551-019-0497-x)
Oleaga, C. et al. Sci. Rep. 6, 20030 (2016). (PMID: 26837601473827210.1038/srep20030)
Edington, C. D. et al. Sci. Rep. 8, 4530 (2018). (PMID: 29540740585208310.1038/s41598-018-22749-0)
Ronaldson-Bouchard, K. et al. Nat. Biomed. Eng. 6, 351–371 (2022). (PMID: 35478225925001010.1038/s41551-022-00882-6)
Homan, K. A. Adv. Biol. 7, e2200334 (2023). (PMID: 10.1002/adbi.202200334)
Ainslie, G. R. et al. Lab Chip 19, 3152–3161 (2019). (PMID: 3146913110.1039/C9LC00492K)
Baudy, A. R. et al. Lab Chip 20, 215–225 (2020). (PMID: 3179997910.1039/C9LC00768G)
Fowler, S. et al. Lab Chip 20, 446–467 (2020). (PMID: 3193281610.1039/C9LC00857H)
Hardwick, R. N. et al. Lab Chip 20, 199–214 (2020). (PMID: 3159861810.1039/C9LC00519F)
Irrechukwu, O. et al. ALTEX 40, 485–518 (2023). (PMID: 36648096)
Peters, M. F. et al. Lab Chip 20, 1177–1190 (2020). (PMID: 3212935610.1039/C9LC01107B)
Peterson, N. C., Mahalingaiah, P. K., Fullerton, A. & Di Piazza, M. Lab Chip 20, 697–708 (2020). (PMID: 3196715610.1039/C9LC00962K)
Pointon, A. et al. Lab Chip 21, 458–472 (2021). (PMID: 3347100710.1039/D0LC01040E)
Ramsden, D. et al. ALTEX 39, 273–296 (2022). (PMID: 34766620)
Wang, X. et al. ALTEX 40, 314–336 (2022). (PMID: 36044561)
Bloomingdale, P. et al. Curr. Opin. Toxicol. 4, 79–87 (2017). (PMID: 29308440575400110.1016/j.cotox.2017.07.003)
Rusyn, I. et al. Toxicol. Sci. 188, 143–152 (2022). (PMID: 35689632933340410.1093/toxsci/kfac061)
Graham, J. C. et al. Cutan. Ocul. Toxicol. 37, 380–390 (2018). (PMID: 3003561510.1080/15569527.2018.1483944)
Linsenmeier, R. A. & Saterbak, A. Ann. Biomed. Eng 48, 1590–1615 (2020). (PMID: 3225361510.1007/s10439-020-02494-0)
Ewart, L. et al. Exp. Biol. Med. 242, 1579–1585 (2017). (PMID: 10.1177/1535370217715441)
Gaskin, S. P., Griffin, A., Hauser, J. R., Katz, G. M. & Klein, R. L. in Wiley International Encyclopedia of Marketing (eds Sheth, J. N. & Malhotra, N. K.) 1–6 (John Wiley & Sons, 2010); https://doi.org/10.1002/9781444316568.wiem05020.
Tomlinson, L. et al. Adv. Biol. https://doi.org/10.1002/adbi.202300131 (2023). (PMID: 10.1002/adbi.202300131)
Ewart, L. & Roth, A. Nat. Rev. Drug Discov. 20, 327–328 (2021). (PMID: 3361938510.1038/d41573-020-00030-2)
Hartung, T. et al. ALTEX 36, 3–17 (2019). (PMID: 3063330210.14573/altex.1812191)
Salian-Mehta, S. et al. Toxicol. Res. Appl. https://doi.org/10.1177/2397847321999760 (2021). (PMID: 10.1177/2397847321999760)
Medina, L. V., Coenen, J. & Kastello, M. D. J. Am. Assoc. Lab Anim. Sci. 54, 115–118 (2015). (PMID: 258369564382614)
Mangipudy, R., Burkhardt, J. & Kadambi, V. J. Regul. Toxicol. Pharmacol. 70, 439–441 (2014). (PMID: 2505885510.1016/j.yrtph.2014.07.014)
Monticello, T. M. et al. Toxicol. Appl. Pharmacol. 334, 100–109 (2017). (PMID: 2889358710.1016/j.taap.2017.09.006)
Graham, J. C. et al. Regul. Toxicol. Pharmacol. 126, 105023 (2021). (PMID: 3436392010.1016/j.yrtph.2021.105023)
Mitra, M. S. et al. Regul. Toxicol. Pharmacol. 122, 104895 (2021). (PMID: 3361061010.1016/j.yrtph.2021.104895)
Lombardo, F. et al. J. Med. Chem. 60, 9097–9113 (2017). (PMID: 2860962410.1021/acs.jmedchem.7b00487)
Einholf, H. J. et al. Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling Pharmaceutical Technology Regulatory Sourcebook eBook 24–27 (pharmtech.com, 2021).
Riedmaier, A. E. et al. AAPS J. 22, 123 (2020). (PMID: 3298101010.1208/s12248-020-00508-2)
Jones, H. M. et al. Clin. Pharmacokinet. 50, 331–347 (2011). (PMID: 2145663310.2165/11539680-000000000-00000)
Price, E. et al. J. Med. Chem. 64, 9389–9403 (2021). (PMID: 3415277210.1021/acs.jmedchem.1c00669)
تواريخ الأحداث: Date Created: 20231227 Latest Revision: 20231227
رمز التحديث: 20231228
DOI: 10.1038/s41551-023-01154-7
PMID: 38151640
قاعدة البيانات: MEDLINE
الوصف
تدمد:2157-846X
DOI:10.1038/s41551-023-01154-7